Oral fluid cannabinoids in chronic cannabis smokers during oral δ9-Tetrahydrocannabinol therapy and smoked cannabis challenge

Clinical Chemistry

Volumn 59, Issue 12, 2013, Pages 1770-1779

  Lee, Dayong ^a   Vandrey, Ryan ^b   Mendu, Damodara R ^a   Anizan, Sebastien ^a   Milman, Garry ^a   Murray, Jeannie A ^b   Barnes, Allan J ^a   Huestis, Marilyn A ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11 HYDROXYDRONABINOL; 11 NOR 9 CARBOXYDRONABINOL; CANNABIDIOL; CANNABINOID; CANNABINOL; DRONABINOL; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANNABIS ADDICTION; CANNABIS SMOKING; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DETERMINATION; DRUG DOSE COMPARISON; DRUG SALIVA LEVEL; FEMALE; GAS CHROMATOGRAPHY; HUMAN; MALE; MASS SPECTROMETRY;

ADMINISTRATION, ORAL; ADULT; CANNABINOIDS; CROSS-OVER STUDIES; DRONABINOL; FEMALE; HUMANS; MALE; MARIJUANA SMOKING; MIDDLE AGED; SALIVA;

EID: 84889874485     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2013.207316     Document Type: Article

References (37)

1. US Food and Drug Administration. Drugs@FDA: FDA approved drug products. http://www.accessdata.fda. gov/scripts/cder/drugsatfda/index.cfm?fuseaction= Search.DrugDetails (Accessed March 2013).
2. Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 2004;329: 253.
3. Hagenbach U, Luz S, Ghafoor N, Berger JM, Grotenhermen F, Brenneisen R, Mäder M. The treatment of spasticity with delta9-tetrahydrocannabinol in persons with spinal cord injury. Spinal Cord 2007; 45:551-62.
4. Flach AJ. Delta-9-tetrahydrocannabinol (THC) in the treatment of end-stage open-angle glaucoma. Trans Am Ophthalmol Soc 2002;100:215-24.
5. Noyes R Jr, Brunk SF, Avery DA, Canter AC. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther 1975;18:84-9.
6. Budney AJ, Vandrey RG, Hughes JR, Moore BA, Bahrenburg B. Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms. Drug Alcohol Depend 2007;86:22-9.
7. Levin FR, Mariani JJ, Brooks DJ, Pavlicova M, Cheng W, Nunes EV. Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend 2011;116:142-50.
8. Vandrey R, Stitzer ML, Mintzer MZ, Huestis MA, Murray JA, Lee D. The dose effects of short-term dronabinol (oral THC) maintenance in daily cannabis users. Drug Alcohol Depend 2012;128: 64-70.
9. Haney M, Hart CL, Vosburg SK, Nasser J, Bennett A, Zubaran C, Foltin RW. Marijuana withdrawal in humans: effects of oral THC or divalproex. Neuropsychopharmacology 2004;29:158 -70.
10. Haney M, Hart CL, Vosburg SK, Comer SD, Reed SC, Foltin RW. Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse. Psychopharmacology 2008; 197:157- 68.
11. Levin FR, Mariani JJ, Brooks DJ, Xie S, Murray KA. Delta9- tetrahydrocannabivarin testing may not have the sensitivity to detect marijuana use among individuals ingesting dronabinol. Drug Alcohol Depend 2010;106:65- 8.
12. Choo RE, Huestis MA. Oral fluid as a diagnostic tool. Clin Chem Lab Med 2004;42:1273- 87.
13. Verstraete AG. Oral fluid testing for driving under the influence of drugs: history, recent progress and remaining challenges. Forensic Sci Int 2005; 150:143-50.
14. Wille SM, Ramírez-Fernandez Mdel M, Samyn N, De Boeck G. Conventional and alternative matrices for driving under the influence of cannabis: recent progress and remaining challenges. Bioanalysis 2010;2:791- 806.
15. Moore C. Oral fluid for workplace drug testing: laboratory implementation. Drug Test Anal 2012; 4:89 -93.
16. Bush DM. The U.S. Mandatory Guidelines for Federal Workplace Drug Testing Programs: current status and future considerations. Forensic Sci Int 2008;174:111-9.
17. Milman G, Barnes AJ, Schwope DM, Schwilke EW, Darwin WD, Goodwin RS, et al. Disposition of cannabinoids in oral fluid after controlled around-the-clock oral THC administration. Clin Chem 2010;56:1261-9.
18. Lee D, Karschner EL, Milman G, Barnes AJ, Goodwin RS, Huestis MA. Can oral fluid cannabinoid testing monitor medication compliance and/or cannabis smoking during oral THC and oromucosal sativex administration? Drug Alcohol Depend 2013;130:68 -76.
19. Lee D, Schwope DM, Milman G, Barnes AJ, Gorelick DA, Huestis MA. Cannabinoid disposition in oral fluid after controlled smoked cannabis. Clin Chem 2012;58:748 -56.
20. Schwope DM, Karschner EL, Gorelick DA, Huestis MA. Identification of recent cannabis use: wholeblood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration. Clin Chem 2011; 57:1406-14.
21. Kauert GF, Ramaekers JG, Schneider E, Moeller MR, Toennes SW. Pharmacokinetic properties of delta9-tetrahydrocannabinol in serum and oral fluid. J Anal Toxicol 2007;31:288 -93.
22. Toennes SW, Ramaekers JG, Theunissen EL, Moeller MR, Kauert GF. Pharmacokinetic properties of delta9-tetrahydrocannabinol in oral fluid of occasional and chronic users. J Anal Toxicol 2010;34:216 -21.
23. Huestis MA, Cone EJ. Relationship of δ9- tetrahydrocannabinold concentrations in oral fluid and plasma after controlled administration of smoked cannabis. J Anal Toxicol 2004;28: 394-9.
24. Niedbala RS, Kardos KW, Fritch DF, Kardos S, Fries T, Waga J, et al. Detection of marijuana use by oral fluid and urine analysis following singledose administration of smoked and oral marijuana. J Anal Toxicol 2001;25:289 -303.
25. Lee D, Milman G, Barnes AJ, Goodwin RS, Hirvonen J, Huestis MA. Oral fluid cannabinoids in chronic, daily cannabis smokers during sustained, monitored abstinence. Clin Chem 2011; 57:1127-36.
26. Budney AJ, Novy PL, Hughes Jr. Marijuana withdrawal among adults seeking treatment for marijuana dependence. Addiction 1999;94: 1311-22.
27. Hart CL, Haney M, Ward AS, Fischman MW, Foltin RW. Effects of oral THC maintenance on smoked marijuana self-administration. Drug Alcohol Depend 2002;67:301-9.
28. Moore C, Rana S, Coulter C, Day D, Vincent M, Soares J. Detection of conjugated 11-nor-delta9- tetrahydrocannabinol-9-carboxylic acid in oral fluid. J Anal Toxicol 2007;31:187-94.
29. Milman G, Barnes AJ, Lowe RH, Huestis MA. Simultaneous quantification of cannabinoids and metabolites in oral fluid by two-dimensional gas chromatography mass spectrometry. J Chromatogr A 2010;1217:1513-21.
30. Lowe RH, Karschner EL, Schwilke EW, Barnes AJ, Huestis MA. Simultaneous quantification of delta9-tetrahydrocannabinol, 11- hydroxy-delta9- tetrahydrocannabinol, and 11- nor-delta9-tetrahydrocannabinol-9-carboxylic acid in human plasma using two-dimensional gas chromatography, cryofocusing, and electron impact-mass spectrometry. J Chromatogr A 2007; 1163:318 -27.
31. Niedbala RS, Kardos KW, Fritch DF, Kunsman KP, Blum KA, Newland GA, et al. Passive cannabis smoke exposure and oral fluid testing. 2. Two studies of extreme cannabis smoke exposure in a motor vehicle. J Anal Toxicol 2005; 29:607-15.
32. Kelly TH, Foltin RW, Fischman MW. Effects of smoked marijuana on heart rate, drug ratings and task performance by humans. Behav Pharmacol 1993;4:167-78.
33. Heishman SJ, Stitzer ML, Yingling JE. Effects of tetrahydrocannabinol content on marijuana smoking behavior, subjective reports, and performance. Pharmacol Biochem Behav 1989;34: 173-9.
34. Gorelick DA, Goodwin RS, Schwilke E, Schwope DM, Darwin WD, Kelly DL, et al. Tolerance to effects of high-dose oral delta9-tetrahydrocannabinol and plasma cannabinoid concentrations in male daily cannabis smokers. J Anal Toxicol 2013;37:11-6.
35. Jones RT, Benowitz N, Bachman J. Clinical studies of cannabis tolerance and dependence. Ann NY Acad Sci 1976;282:221-39.
36. Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW. Abstinence symptoms following oral THC administration to humans. Psychopharmacology 1999;141:385-94.
37. Azorlosa JL, Greenwald MK, Stitzer ML. Marijuana smoking: effects of varying puff volume and breathhold duration. J Pharmacol Exp Ther 1995;272:560 -9.